CASI Pharmaceuticals
Rockville, United States · Biopharma, Biotechnology, Health Care
CASI Pharmaceuticals, Inc. is a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products in China, the United States, and throughout the world. The Company is focused on acquiring, developing, and commercializing products that augment its hematology oncology therapeutic focus as well as other areas of unmet medical need. The Compa
Key facts
- Headquarters
- Rockville, United States
- Employees
- 45
- Industries
- Biopharma, Biotechnology, Health Care
- Status
- Public (CASIF)
- Website
- casipharmaceuticals.com
- Company page
Recent activity at CASI Pharmaceuticals
- : CASI Pharmaceuticals
- : CASI Pharmaceuticals Appoints David Cory as Chief Executive Officer
- : CASI Pharmaceuticals
- : CASI Pharmaceuticals Appoints Daniel Lang, MD as Chief Financial Officer and Senior Vice President
- : CASI Pharmaceuticals, Inc. raised $15 million in a private placement financing led by Venrock Healthcare Capital Partners and Foresite Capital
- : Casi Pharmaceuticals Acquires Global Intellectual Property Rights To Cleave Therapeutics' Vcp/P97 Inhibitor Cb-5339
- : Casi Pharmaceuticals Announces Exit Of Juventas Investment To Strengthen Balance Sheet
CASI Pharmaceuticals funding history
| Date | Round | Amount |
|---|---|---|
| Jan 2026 | Venture | $5.0M |
| Jul 2024 | Venture | $15.0M |
| Jun 2024 | Post-IPO Equity | $15.0M |
| Sep 2022 | Venture | Undisclosed |
Leadership
- Larry Zhang, President
- Jim Goldschmidt, Senior Vice President
- David Cory, Chief Executive Officer
- Daniel Lang, Chief Financial Officer
Verified email and direct lines for CASI Pharmaceuticals’s decision-makers are on Fundz. See plans
Employee benefit plans
CASI Pharmaceuticals files 1 employee benefit plan with the U.S. Department of Labor, including a retirement plan. The next plan year renews in Dec 2026.
CASI Pharmaceuticals in the news
- CASI Pharmaceuticals Receives the Delisting Decision From the Nasdaq Hearings Panel - Investing News Network (Feb 25, 2026)
- FDA Green Light: CASI's Novel Drug Takes Aim at Leading Cause of Kidney Transplant Failure - Stock Titan (Aug 04, 2025)
- CASI Pharmaceuticals Appoints David Cory as Chief Executive Officer to Lead U.S. Company Focused on Clinical Development of CID-103, a Potential Best in Class Anti-CD38 Program - newswire.com (Jul 21, 2025)
- CASI PHARMACEUTICALS AND CLEAVE THERAPEUTICS ANNOUNCE CLINICAL TRIAL APPLICATION APPROVAL FOR CB-5339 IN PATIENTS WITH MULTIPLE MYELOMA IN CHINA - prnewswire.com (Jan 06, 2023)
- CASI Pharmaceuticals Announces Changes in Board Governance - Investing News Network (Nov 27, 2025)
- CASI PHARMACEUTICALS ENTERS INTO SUBLICENSE AGREEMENT WITH TIANSHI PHARMACEUTICALS FOR ANTI-CD38 MONOCLONAL ANTIBODY (MAB) CID-103 IN AUTOIMMUNE FIELD - prnewswire.com (May 24, 2022)
- CASI Pharmaceuticals Announces Update and Additional Results from Phase 1 Study of CID-103 in Adult Patients with Chronic Immune Thrombocytopenia - Investing News Network (Jan 12, 2026)
- Mundipharma International Corporation Limited, Mundipharma Medical Company, and Acrotech Biopharma Inc. Enter Agreement to Transfer License of FOLOTYN® (Pralatrexate) in China to CASI Pharmaceuticals - prnewswire.com (Aug 01, 2023)
Companies similar to CASI Pharmaceuticals
- Jubilant Therapeutics · Biopharma, Biotechnology, Health Care, Manufacturing, Pharmaceutical, Therapeutics
- AbbVie Inc. · Biopharma, Biotechnology, Health Care, Manufacturing, Pharmaceutical, Therapeutics
- AnHeart Therapeutics · Biopharma, Biotechnology, Health Care, Manufacturing, Pharmaceutical, Therapeutics
- Contineum Therapeutics · Biopharma, Biotechnology, Health Care, Manufacturing, Pharmaceutical, Therapeutics
- YS Biopharma · Biopharma, Biotechnology, Health Care, Manufacturing, Pharmaceutical, Therapeutics
About CASI Pharmaceuticals: questions and answers
What does CASI Pharmaceuticals do?
CASI Pharmaceuticals, Inc. is a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products in China, the United States, and throughout the world. The Company is focused on acquiring, developing, and commercializing products that augment its hematology oncology therapeutic focus as well as other areas of unmet medical need. The Compa
Where is CASI Pharmaceuticals headquartered?
CASI Pharmaceuticals is headquartered in Rockville, United States.
How many employees does CASI Pharmaceuticals have?
CASI Pharmaceuticals has about 45 employees.
Has CASI Pharmaceuticals raised funding?
Yes. Fundz has recorded 4 funding events for CASI Pharmaceuticals. The most recent, $5.0M, was in Jan 2026.
Who leads CASI Pharmaceuticals?
Larry Zhang is a President at CASI Pharmaceuticals.
What is the latest news on CASI Pharmaceuticals?
On Jan 28, 2026, CASI Pharmaceuticals
Is CASI Pharmaceuticals a public company?
Yes. CASI Pharmaceuticals is publicly traded under the ticker CASIF.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy